Kamada Ltd., a global biopharmaceutical company specializing in plasma-derived therapeutics, is expanding its plasma collection capabilities with a new state-of-the-art facility in San Antonio, Texas. The 11,100-square-foot center is designed to support up to 50 donor beds and has the potential to collect 50,000 liters of plasma annually.
The new center represents a strategic move to increase the company's capacity for collecting specialty hyper-immune plasma, which is critical for treating various medical conditions. Hyper-immune plasma contains concentrated antibodies used in preventing and treating infections in transplant patients, protecting against rabies, and managing other complex medical scenarios.
According to Kamada's CEO Amir London, the facility will serve two primary purposes. First, it will collect specialty plasma like Anti-Rabies and Anti-D for internal use, reducing the company's dependency on third-party suppliers. Second, the center will collect normal source plasma for sale to other medical manufacturers, with projected annual revenues between $8 million and $10 million at full capacity.
The company anticipates obtaining necessary approvals from the U.S. Food and Drug Administration and European Medicines Agency within nine to twelve months. This expansion follows Kamada's previous plasma collection site openings in Beaumont and Houston, Texas, positioning the company as a potential leader in specialty plasma-derived therapeutics.
Currently, the FDA has approved six of Kamada's plasma-derived therapeutics targeting rare and underserved medical conditions, including treatments for lung disease, viral exposures, and post-transplant infectious diseases. By developing its own plasma collection infrastructure, Kamada aims to improve its production costs and potentially become a supplier for other industry participants.
